Supplementary Data from Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
作者
Valentina Boni,Mary J. Fidler,Hendrik‐Tobias Arkenau,Alexander I. Spira,Funda Meric‐Bernstam,Nataliya V. Uboha,Rachel E. Sanborn,Randy F. Sweis,Patricia LoRusso,Misako Nagasaka,Javier Garciá Corbacho,Shadia I. Jalal,James J. Harding,Stella K. Kim,Iris H.C. Miedema,Daniëlle J. Vugts,Marc C. Huisman,Gerben J.C. Zwezerijnen,Guus A.M.S. van Dongen,C. Willemien Menke‐van der Houven van Oordt
Supplementary Data from Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial